- Unsurprisingly, Valeant Pharmaceuticals (VRX -39.6%) takes exception to Citron Research's bearish report saying its allegations of recording fake sales to phony customers are "erroneous" while defending its relationship with specialty pharmacies that distribute its drugs. In a statement, the company says "There is no sales benefit from any inventory held at these specialty pharmacies." It says it books sales only when the drugs are sent to patients.
- Previously: Citron Research slams Valeant Pharma; shares down 20%, trading halted (Oct. 21)